Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis.

Britney BarreraHaley SimpsonEric EngebretsonStefan SillauBrooke ValdezJosé Parra-GonzálezRyan C WingerLou Anne EppersonAshley BanksKathryn PierceMelanie SpottsKatie O'GeanEnrique AlvarezRobert GrossAmanda L PiquetTeri SchreinerJohn R CorboyJinglan PeiTimothy L VollmerKavita V Nair

Published in: Annals of clinical and translational neurology (2023)

IRRs and AEs occurred at acceptable rates during in-home infusions of ocrelizumab over a shorter infusion time. Patients reported increased confidence and comfort with the home infusion process. Findings from this study provide evidence of the safety and feasibility of home-based ocrelizumab infusion over a shorter infusion period.

Keyphrases

low dose
multiple sclerosis
healthcare
end stage renal disease
newly diagnosed
ejection fraction
prognostic factors
patient reported